LSLan Sun

Lan Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lan Sun has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Sun

    Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Chinese Medicine, Kunming, Yunnan, China; Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

    2 shared publications
  • Yu Ren

    Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Chinese Medicine, Kunming, Yunnan, China; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    2 shared publications
  • Bo Qiao

    Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment Yunnan University of Chinese Medicine Kunming China

    1 shared publication
  • Fuyan Yang

    Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment Yunnan University of Chinese Medicine Kunming China

    1 shared publication
  • Gao-Bin Li

    Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Chinese Medicine, Kunming, Yunnan, China; School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, Yunnan, China

    1 shared publication
  • Jiali Yuan

    Yunnan Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, Yunnan, China

    1 shared publication

Latest Publications

  • Guipi Tang alleviates vascular dementia by regulating purine metabolism via gut microbiota-derived pantothenic acid

    by Yu Ren, Yi Sun, Qian Liu, Jin-Ling Chen, Yu-Han Chen, Lan Sun, Zhao Cui, Shi-Yu Yan, Ling Cheng, Ning Li, et al.


  • Research Progress of Panax notoginseng and Its Active Components in Preventing and Treating Cognitive Dysfunction of Aging

    by Lan Sun, Fuyan Yang, Shanshan Wang, Jiarong Du, Rong Yuan, Bo Qiao, Yueying Wu, Xiaoya Li

    With the aggravation of global population aging, the number of people with cognitive impairment is increasing, which has become a challenge that cannot be ignored in the field of public health. Panax notoginseng is a characteristic plant resource in Yunnan, which contains saponins, polysaccharides, flavonoids, amino acids, trace elements, and has a remarkable neuroprotective effect. The purpose of this paper is to summarize the potential mechanism of P. notoginseng and its active components in preventing and treating cognitive dysfunction caused by aging, in order to provide a theoretical basis and practical guidance for further development and application of P. notoginseng and its components and anti‐aging related cognitive dysfunction.


  • Total Saponins of Panax notoginseng Leaves Alleviate Vascular Dementia via the Gut–Brain Axis

    by Yu Ren, Yi Sun, Lan Sun, Jin-Ling Chen, Yu-Han Chen, Shi-Yu Yan, Ling Cheng, Jia-Li Yuan, Xiao-Ya Li

    Vascular dementia (VD) is the second most common type of dementia after Alzheimer’s disease (AD), and chronic cerebral hypoperfusion (CCH) is the main causative factor of VD. Previous reports have confirmed that there is a relationship between VD and gut microbiota, and that some plant-based foods can improve VD through the gut–brain axis (GBA). Panax notoginseng leaves are a specialty food in Yunnan, China, and saponin is its main bioactive component. In this study, we investigated the effects of the total saponins of Panax notoginseng leaves (TSPNL) on CCH-induced VD and their potential mechanisms. In this experiment, the model was replicated using bilateral common carotid artery occlusion (BCCAO) and divided into Sham, Model, TSPNL-L, TSPNL-H and Positive drug control. At the end of the treatment, behavior, brain-derived neurotrophic factor (BDNF), hypothalamic–pituitary–adrenal (HPA) axis-related indices, neuronal apoptosis-related indices, gut microbiota composition, and colon and brain pathology were tested. The results showed that TSPNL attenuated CCH-induced VD, promoted BDNF synthesis, and inhibited neuronal apoptosis. Predictions of network pharmacology and experiments demonstrated that these beneficial effects are mediated in part through BDNF-TrKB-PI3K/Akt signaling. In addition, TSPNL prevented intestinal dysbiosis by increasing the abundance of the probiotic Ligilactobacillus and decreasing the abundance of the deleterious bacterium Clostridia_ UCG_014_unclassified relative to the model group. TSPNL was also able to partially reverse intestinal barrier disruption and inhibit intestinal inflammation and the hyperactivation of the HPA axis. The results of this study support the conclusion that TSPNL has potential in the prevention of CCH-induced VD and warrants further investigation.